Kyverna shelves next-gen CAR-T KYV-102 to focus on miv-cel in stiff person syndrome
- Kyverna deprioritized KYV-102, a next-generation CAR-T on the miv-cel backbone made with a process meant to remove apheresis and shorten culture.
- FDA accepted the miv-cel BLA in stiff person syndrome for priority review; approval would make it the first CAR-T for an autoimmune disease.
- Management mentioned expansion into myasthenia gravis, rheumatoid arthritis and multiple sclerosis.
💡 Points Based on public reports
Dropping the cheaper, apheresis-free version is the telling move: with a first approval in sight, Kyverna is spending scarce cash on the product regulators are about to judge, and the manufacturing advantage that would help scale can wait. The weakness is concentration, since SPS is tiny, so the commercial case rests on myasthenia gravis and lupus-type expansions where safety concerns seen with other autoimmune CAR-Ts will matter.
📰 Source · BioSpace ↗ Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings